azacitidine has been researched along with cladribine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Duley, JA; Fabianowska-Majewska, K; Ruckemann, K; Simmonds, HA | 1 |
| Fabianowska-Majewska, K; Wyczechowska, D | 1 |
| Fabianowska-Majewska, K; Krawczyk, B | 1 |
| Fabianowska-Majewska, K; Krawczyk, B; Rudnicka, K | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Robak, T; Wierzbowska, A | 1 |
| Andreeff, M; Benton, CB; Boddu, P; Borthakur, G; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Patel, K; Ravandi, F; Takahashi, K | 1 |
| Andreeff, M; Bhalla, KN; Borthakur, G; Daver, NG; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Malla, R; Montalban-Bravo, G; Ohanian, M; Pemmaraju, N; Popat, UR; Quagliato, K; Rausch, CR; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Takahashi, K; Wang, X | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
2 review(s) available for azacitidine and cladribine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
2 trial(s) available for azacitidine and cladribine
| Article | Year |
|---|---|
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2022 |
12 other study(ies) available for azacitidine and cladribine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Effect of Cladribine, fludarabine, and 5-aza-deoxycytidine on S-adenosylmethionine (SAM) and nucleotides pools in stimulated human lymphocytes.
Topics: Adenine Nucleotides; Adenine Phosphoribosyltransferase; Antineoplastic Agents; Azacitidine; Cells, Cultured; Cladribine; Cytidine Triphosphate; Decitabine; Guanine Nucleotides; Humans; Kinetics; Lymphocyte Activation; Lymphocytes; NAD; Ribonucleotides; S-Adenosylmethionine; Uracil Nucleotides; Vidarabine | 1998 |
Does 2-chlorodeoxyadenosine contribute to alteration of DNA methyltransferase activity?
Topics: Adenosylhomocysteinase; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cladribine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Hydrolases; Kinetics; Leukemia L1210; Mice; Tumor Cells, Cultured; Vidarabine | 1998 |
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
Topics: Azacitidine; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; Estrogen Receptor alpha; Genes, APC; Genes, BRCA1; Humans; K562 Cells; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Vidarabine | 2006 |
The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Genes, APC; Genes, BRCA1; Genes, Tumor Suppressor; Humans; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Receptors, Retinoic Acid; Vidarabine | 2007 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins | 2014 |
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Mutation; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |